Our Team

Ariane Tom, PhD

Founder & Managing Director

Dr. Ariane Tom is a leader in neurotechnology and applied AI investing, known for her rare combination of scientific rigor, technical fluency, and early access to the breakthrough founders shaping the neurotechnology era. A Stanford-trained neuroengineer, she began her work in 2008 designing bioelectronic interfaces for the brain, co-authoring landmark research with Karl Deisseroth and Zhenan Bao that helped propel the modern era of neuroengineering. Her innovations in brain–machine interfaces and neuromodulation have been featured in publications such as Science, Nature, Time, and Scientific American, and continue to influence the neurotech frontier.

As an investor, Dr. Tom has independently built a high-performing portfolio that includes early positions in Anthropic and Manifest Technologies (acquired), earning the trust of institutions, family offices, and strategics seeking credible access to this emerging category. At the helm of Kaleida Capital, she brings a global perspective on the future of intelligence—where neural data, computation, and human performance converge to define a new era of opportunity.

Srihari Sritharan, PhD

Venture Fellow - Investments

Dr. Srihari (Sri) Sritharan is a neuroengineer and venture builder recognized for translating complex neural technologies into clinical and commercial breakthroughs. A Brown- and Penn-trained neuroscientist, his doctoral work with Timothy Lucas and Penn Neurosurgery advanced wireless neuromodulation for sensory restoration, shaping the next wave of brain–computer interface research. His work in neural decoding and bioelectronic platforms underscores a career-long commitment to rigorous science with tangible human impact.

In industry, Dr. Sritharan has led business development across biopharma and neurotech, directing diligence on a ~$1Bn RNA therapeutics partnership at Acadia Pharmaceuticals and scaling Beacon Biosignals' EEG biomarker platform to advance neurology drug development. At Kaleida Capital, he merges scientific fluency with venture strategy, backing founders redefining how the brain is measured, modeled, and augmented.